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ABSTRACT
Disease management programs improve outcomes in subjects with chronic obstructive pul-
monary disease (COPD), but their effect in subjects with alpha-1 antitrypsin deficiency (AATD)
has not been evaluated. To assess the impact of a disease management program, applica-
ble to subjects with AATD-associated COPD throughout the United States, on exacerbations,
healthcare resource utilization and health-related quality of life (HRQoL). The Alpha-1 Disease
Management and Prevention Program (ADMAPP) consisted of comprehensive written educa-
tional patient-directed material for self-study and treatment plans. Program reinforcement was
performed through monthly phone calls by specialized coordinators. Outcomes were collected
prospectively for 12 months before, and 12 months after enrollment into the program. Exac-
erbations and healthcare resource utilization were recorded monthly. HRQoL was measured
with the St George’s Respiratory Questionnaire (SGRQ) every 6 months and the Short Form-
36 (SF-36) every 12 months. A total of 878 subjects completed the 2-year study. During the
intervention year, there was a significant increase in the use of long-acting bronchodilators,
better compliance with oxygen therapy, and more use of steroid courses during exacerbations.
Total exacerbation rates, unscheduled physician visits and emergency room visits significantly
decreased. There was also a statistically significant slowing in the deterioration of the SGRQ’s
activity domain, while total SGRQ scores remained stable during the study. Significant improve-
ments were observed in some of the SF-36 domains, particularly in the general health domain.
The ADMAPP improved health outcomes in subjects with AATD-associated COPD.
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INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD) is associ-
ated with significant morbidity and mortality and imposes a
profound burden on the health care system. Despite the devel-
opment of effective pharmacological therapies to relieve airflow
obstruction and reduce exacerbations, COPD subjects continue
to experience a slow deterioration of lung function with pro-
gressive disability and significant impairment in health-related
quality of life (HRQoL). The impact of COPD may be even
more pronounced in subjects with alpha-1 antitrypsin deficiency
(AATD), a genetic condition associated with early-onset COPD,
as affected subjects usually become symptomatic during their
most productive years. The burden of disease on subjects with
AATD is further aggravated by the stigma of carrying a genetic
condition and the additional commitment to regular intravenous
infusions of expensive augmentation therapy. Therefore, more
effective therapeutic approaches are needed for the treatment of
subjects with COPD, and benefits from such approaches may
be magnified in individuals with AATD.
Pulmonary rehabilitation, combining exercise programs with
patient education, is one of the non-pharmacologic therapeutic
modalities for COPD that has been associated with the most fa-
vorable outcomes in term of improvement in exercise capacity,
dyspnea and HRQoL (1). Unfortunately, rehabilitation programs
are not widely utilized because of reimbursement inconsisten-
cies (2). Another approach to improve patient-oriented COPD
outcomes has been the development of disease management pro-
grams aimed at patient education with self-management princi-
ples.
Unfortunately, the results of available studies regarding the
effect of disease management programs in improving HRQoL
(3–6) or in reducing exacerbation rates (3, 6), hospitalizations (5,
7) and physician visits (6, 8, 9) have been variable, largely due
to the wide heterogeneity in their designs and the patient pop-
ulations evaluated. In a recent meta-analysis, it was concluded
that self-management education is associated with a reduction
in hospital admissions with no indication of detrimental effects
in other outcome parameters, but current data is insufficient to
establish clear recommendations regarding the form or content
of self-management programs in COPD (10). The impact of
self-management programs in specific COPD populations, such
as those with AATD, has not previously been evaluated.
In the present report, we present the results of a 12-month
disease management program applied to a large cohort of indi-
viduals with COPD due to AATD in the United States (Alpha-1
Disease Management and Prevention Program or ADMAPP).
METHODS
Study participants
Study participants were all members of AlphaNet, a not-for-
profit, patient-run health management company that coordinates
services for subjects with AATD. These subjects were dis-
tributed geographically throughout the United States and were
followed on a regular basis by one of 23 regionally based dis-
ease management coordinators, all of whom are individuals with
AATD. As members of AlphaNet, all study participants were di-
agnosed with AATD by their own physicians and were placed on
augmentation therapy because of symptomatic obstructive lung
disease, primarily with Prolastin©R (alpha-1 proteinase inhibitor,
Talecris Biotherapeutics, Research Triangle Park, NC) although
about 3% received Zemaira©R (alpha-1 proteinase inhibitor, CSL
Behring, King of Prussia, PA).
All members of AlphaNet were invited to participate in the
study. Subjects who had lung transplantation were excluded
from the analysis. For the study, all subjects verbally con-
firmed their diagnosis of AATD. In an attempt to further con-
firm this, 68% responded to the investigators’ request to send
a copy of their AAT genotypes/phenotypes and AAT levels at
the time of diagnosis. From this group, 94% were genotype
ZZ with AAT levels below 11 µM. The protocol and enroll-
ment process has been previously reported (11) and was ap-
proved by the University of Miami’s Institutional Review Board.
All subjects signed a written informed consent and HIPAA
authorization.
Study design
The protocol was designed to evaluate the impact of the
ADMAPP in subjects with AATD. The main outcome was ef-
fect on HRQoL scores and secondary outcomes were effect on
exacerbation rates, medication utilization, healthcare resource
utilization (physician visits, emergency room visits and hospi-
talizations), and patient satisfaction.
The study is a non-randomized and non-concurrent trial com-
paring outcomes in the same subjects a 2-year period: an initial
1-year observation period, or pre-ADMAPP year, and a post-
intervention or ADMAPP year. Throughout the study, telephone
surveys were conducted on a monthly basis by the AlphaNet co-
ordinators to reinforce the components of the program and to
collect data on disease exacerbations, healthcare resource uti-
lization, medication use, and the evaluation of exercise. HRQoL
data were collected by experienced surveyors (Qessential Med-
ical Market Research LLC, Exeter, NH) using the St. George’s
Respiratory Questionnaire (SGRQ) (12, 13) administered at
0,6,12,18 and 24 months, and with the Short Form-36 (SF-
36) administered at 0, 12 and 24 months (14). All SF-36 scores
were normalized to the general U.S. population (1998) on a
scale of 0 (worst) to 100 (best) with 50 being the general U.S.
population mean and each 10-point variation representing one
standard deviation (SD).
Exacerbations were defined according to a consensus defi-
nition by an expert panel (15). Participants were asked to pro-
vide the results of a pulmonary function test performed during
the initial study year for classification according to the Global
Initiative for Chronic Obstructive Lung Disease (GOLD) guide-
lines (16). All survey data were entered directly at the time of
collection into a secure database via an encrypted Web-based
system. The study was conducted between February 2003 and
July 2005.
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Alpha-1 disease management and prevention
program (ADMAPP)
The ADMAPP was developed as part of AlphaNet’s com-
mitment to improve the care of individuals with AATD. It is an
integrated system of directed patient self-education, organized
supervision, healthcare provider education, and outcome mea-
surement. The program was begun to empower individuals with
AATD to take an active role in understanding and managing
their own health with the overall goal to improve their HRQoL
and optimize clinical and economic outcomes. The program
included a comprehensive reference guide with detailed scien-
tific and lay explanations about COPD and AATD, specifically
directed towards a well-educated, informed patient. It was not
intended to be a substitute for physician diagnosis and treatment.
The guide, entitled the “Big Fat Reference Guide to Alpha-1
(BFRG)”, is a written document authored by over 30 recognized
experts in AATD and/or specific aspects of the management pro-
gram and is divided into easily understood sections. Included
are sections covering general information regarding AATD, pre-
vention of disease in AATD, and severity-based descriptions of
AATD-associated lung disease. Management recommendations
focused on chronic care, highlighting the risks and benefits of
the different classes of medications that can be used in COPD,
including the advantages of long-acting bronchodilators. The
BFRG also provided guidance regarding healthcare provider
visits, follow-up care, and intercurrent illness management. In
addition, there are specific supplements related to management
of exacerbations, augmentation therapy, oxygen therapy, pre-
operative evaluation, sleep problems, inpatient management,
optimization of nutrition, exercise, sexuality, travel consider-
ations and psychosocial issues. The document provides a set of
guidelines, checklists, and help sheets for the patients and their
physicians. The entire document is available online by register-
ing at http://www.alphanetbfrg.org.
Each participant in the program was provided a hard copy
of the program (the 1000-page BFRG), and also received an
additional copy for their healthcare provider. Disease manage-
ment coordinators, all individuals with AATD, were trained and
tested according to a predefined curriculum. The coordinators
then contacted study subjects by telephone a minimum of once
monthly throughout the 2-year study. After distribution of the
BFRG at study month 12, coordinators were in charge of en-
forcing the reading, discussion and understanding of each of
the components of the ADMAPP. During the study period, a
checklist assessment was performed to determine the subject’s
comprehension of each of the main components of the program.
Every subject was required to work through a long-term treat-
ment plan document, which involved visiting every section of
the BFRG.
Statistical analysis
All data were analyzed using the SAS version 9.13 software
(SAS institute Inc., Cary, North Carolina, USA). Descriptive
statistics are displayed as the mean and standard deviation, or
percentage. Categorical data were analyzed using the Chi-square
test and continue variables were compared using the Student t
test and analysis of variance (ANOV). Variables that did not have
a normal distribution were compared with the Mann–Whitney
U-test. Subanalysis of outcomes was also done by age groups
(<49, 50–59 and >59 years) and by GOLD stage. Age group-
ings were selected to roughly equalize the number of enrolled
subjects in each group. The repeat measurement mixed models
method was employed to compare the changes of HRQoL within
and between-age-group differences. Statistical significance was
accepted at the 5% level.
RESULTS
A total of 1028 subjects without a history of lung transplanta-
tion consented to participate, completed the baseline survey and
were enrolled in the study. A total of 905 individuals completed
the two study years (88%). The reasons for non-completion are
outlined in Figure 1. During the intervention period, 87% of all
subjects successfully completed the long-term treatment plan
that required at least minimal understanding of every section of
the written educational material. The final analysis of the effect
of the disease management program included 878 subjects who
completed at least 22 of the 24 monthly surveys and all the
HRQoL questionnaires (85% of the initial group).
Characteristics of the study population
The sociodemographic characteristics of the 878 evaluable
participants are summarized in Table 1. The average age was
Figure 1. Study flow diagram. The final analysis included 878 sub-
jects who completed at least 22 monthly surveys and all health-
related quality of life surveys.
COPD: Journal of Chronic Obstructive Pulmonary Disease February 2009 33
D
ow
nl
oa
de
d 
by
 [N
ati
on
al 
Je
wi
sh
 H
ea
lth
] a
t 1
2:0
0 0
2 M
ay
 20
16
 
Table 1. Baseline sociodemographic characteristics of the study cohort*
Age, years 54.4 ± 9.6 Individual yearly income ($)
Age groups, years <20,000 24.8%
<50 32.9% 20,000–40,000 30.3%
50–59 37.8% 40,000–60,000 20.9%
≥60 29.2% 60,000–80,000 11.9%
Gender, % 80,000–100,000 4.7%
Male 52.9% >100,000 7.4%
Female 47.1%
Ever used tobacco 82.3% Actively working 32.3%
Tobacco pack-years 23.2 ± 14.5 Report disability, % 8.9%
Regular alcohol consumption
Never 28.7% Report causing caregiver to miss workdays regularly, % 9.6%
<1 drink/week 35.6%
> 1 drink/week 32.0%
Did not specify 3.6% Report missing workdays regularly due to AATD, % 6.4%
Social status
Lives with partner only 55.7%
Lives alone 21.5% Work impairment due to AATD (subjective scale 1–10)† 2.63 ± 2.11, (2)
Lives with children only 3.5%
Lives with partner and children 14.8%
Did not answer 4.4% Daily activities impairment due to AATD (subjective scale 1–10)† 4.99 ± 2.58, (5)
∗N = 878 subjects; results expressed as % of subjects or mean ± SD (median).
†Scale range 1–10: 0: no impairment at all; 10: complete impairment.
AATD: alpha-1 antitrypsin deficiency.
Table 2. Baseline clinical characteristics of the study cohort *
Clinical Features Health-Related Quality of Life
BMI, % SGRQ
< 20 kg/m2 5.1% Total 47.7 ± 17.5
20–24.9 kg/m2 33.1% Symptom 47.7 ± 22.8
25–29.9 kg/m2 36.7% Impact 36.8 ± 17.8
30–34.9 kg/m2 15.3% Activity 66.3 ± 21.7
>34.9 kg/m2 9.8%
FEV1 (L), mean ± SD† 1.2 ± 0.7 SF-36
FEV1 (% predicted), mean ± SD† 36.8 ± 16.9 Physical function 31.7 ± 10.1
FEV1/FVC (%), mean ± SD† 42.8 ± 14.0 Role-physical 39.5 ± 11.2
GOLD stage, % † General health 33.7 ± 11.8
Stage I 2.4% Body pain 51.8 ± 11.2
Stage II 17.6% Mental health 50.3 ± 11.0
Stage III 24.8% Role-emotional 46.8 ± 11.9
Stage IV 55.1% Social function 45.4 ± 12.3
Chronic bronchitis, N (%) 28.0% Vitality 46.2 ± 11.5
Report co-morbidities ‡ Physical Composite Summary 35.6 ± 9.8
none 34.4% Mental Composite Summary 52.2 ± 11.6
1–3 co-morbidities 61%
≥4co-morbidities 4.5%
∗N = 878; results expressed as % of subjects or mean ± SD.
†N = 627 subjects with spirometry performed during study year 1.
‡ Co-morbidities asked include: coronary artery disease, congestive heart failure, hypertension, diabetes mellitus, vascular problems
(peripheral vascular disease and cerebrovascular accidents), peptic ulcer disease, connective tissue diseases, chronic renal problems
and sinus allergies.
BMI: body mass index; GOLD: Global Initiative for COPD classification; FEV1: forced expiratory volume in 1 second; FVC: forced vital
capacity; SGRQ: St. George’s Respiratory Questionnaire; SF-36: Short-Form 36 survey.
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Table 3. Impact of ADMAP program on chronic COPD care*.
Pre-ADMAPP year ADMAPP year p-value
Maintenance Therapy
Short-acting bronchodilators 673 (76.7%) 673 (76.7%) NS
Long-acting bronchodilators 561 (63.9%) 647 (73.7%) <0.001
Inhaled corticosteroids 599 (68.2%) 614 (69.9%) NS
Theophylline 161 (18.3%) 144 (16.4%) 0.01
Antileukotrienes 157 (17.8%) 145 (16.5%) NS
Systemic steroids 52 (5.9%) 38 (4.3%) 0.02
Long-Term Oxygen Therapy
N (%) 48.4% 53.4% <0.01
Average hours/day 15.6 ± 8.1 16.5 ± 7.9 <0.01
% using > 16 h/day 52.1% 56.3% <0.01
Exercise practices during the follow-up year
Did not exercise regularly 456 (51.9%) 488 (55.6%) NS
Exercised regularly (to the subject’s limit) 399 (45.4%) 371 (42.3%) NS
Started to exercise 23 (2.6%) 19 (2.2%) NS
∗N = 878; results expressed as % of subjects or mean ± SD.
NS = non-significant.
54 years and in general, subjects were mostly overweight, had
relatively severe lung disease (79% GOLD stage III or IV), and
had significant impairment in baseline HRQoL scores in both
the disease-specific (SGRQ) and more generic (SF-36) surveys
(Table 2). Most expressed moderate impairment in their daily
activities due to AATD. Overall, the 15% of subjects who did
not complete the 2-year follow-up did not have any significant
differences compared with the group as a whole. However, the
50 subjects (4.8%) who died during follow-up had significantly
worse SGRQ total scores and worse SF-36 composite scores at
baseline.
Impact of ADMAPP on chronic COPD care
After institution of the ADMAPP, there were significant
changes towards a more optimal use of COPD medications,
in particular an increase in the use of long-acting bronchodila-
tors and significant reductions in the use of theophylline and
chronic systemic steroids (Table 3). This was observed across
Table 4. Impact of ADMAP program on acute COPD care*
Pre-ADMAPP year ADMAPP year p-value
Management of acute exacerbations
Added nebulized bronchodilators (in addition to regular 37.1% 28.7% <.0001
inhaled short-acting bronchodilator use)
Use of short course of systemic steroids 58.9% 64.5% <.0001
Took antibiotics 71.9% 70.2% 0.14
Behavior with acute exacerbations
Called primary care physician 17.5% 13.55% <0.001
Called pulmonary specialist 23.1% 22.0% NS
Visited physician office 26.8% 30.6% <0.001
Went to an emergency room 5.4% 6.0% NS
Self-treated exacerbation 28.7% 26.7% NS
∗N = 878; results expressed as % of subjects.
NS: non-significant.
all age groups and among all GOLD stages in the subgroup of
subjects who had spirometry results available. After ADMAPP,
there was significantly better compliance with oxygen use. No
significant changes in the participant’s exercise practices were
observed.
Impact of ADMAPP on acute COPD
exacerbations
There was a significant reduction in the mean number of
exacerbations during the intervention year compared with the
first year (Table 4), mostly due to a reduction in the frequency
of moderate exacerbations. This was observed across all age
groups and in subjects with GOLD stages III and IV (not shown).
Significant reductions in the total time spent with exacerbation
symptoms during the year were observed, mainly due to both a
reduction in the number of exacerbations and a reduction in the
duration of moderate exacerbations. The frequency and duration
of severe exacerbations did not change.
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Table 5. Frequency, severity and duration of exacerbations in the 12 months prior and
after introduction of the ADMAP program (N = 878)
Pre-ADMAPP year ADMAPP year p-value
Total Number of exacerbations 2125 1907
Exacerbations/subject/year
Median (Range) 2 (0–6) 2 (0–5)
Mean (SD) 2.42 ± 1.33 2.17 ± 1.32 <0.001
By severity:
Mild (Mean, SD) 0.37 ± 0.67 0.29 ± 0.6 0.006
Moderate (Mean, SD) 1.78 ± 1.22 1.62 ± 1.2 <0.001
Severe (Mean, SD) 0.27 ± 0.59 0.26 ± 0.57 NS
Duration of exacerbations,
days (Mean, SD)
All 17.3 ± 11.0 16.6 ± 11.5 0.04
Time spent with exacerbations, N (%)
Never had 78 (8.88) 98 (11.16) 0.003
<10% of days of the year 394 (44.87) 448 (51.03)
10–19% of days of the year 243 (27.68) 206 (23.46)
≥20% of days of the year 163 (18.56) 126 (14.35)
NS: non-significant.
After ADMAPP, there was an increased use of short-term
systemic steroids to manage acute COPD exacerbations. No
changes were noted in antibiotic use or self-treatment. There
was a reduction in calls to primary care physicians and more
subjects visited a physician office for evaluation and treatment
of acute exacerbations (Table 5).
Impact of ADMAPP on healthcare resource
utilization
Significant reductions in overall healthcare resource utiliza-
tion were reported during the 12 months post-ADMAPP in-
troduction compared with the 12 months prior for a number
of items including primary care physicians office visits, un-
scheduled physician visits, and emergency room visits (Table
6). Hospitalization rates did not differ.
Impact of ADMAPP on HRQoL
The overall SGRQ total scores at the end of the study period
(48.0 ± 16.3) were not clinically different (>4 points) from the
scores recorded at baseline (47.7 ± 17.5). The activity domain
was the domain with the greatest impairment at baseline and
Table 6. Impact of ADMAP program on healthcare utilization
Pre-ADMAPP ADMAPP
year year p-value
Regular physician visits
To primary care physician 3.2 ± 3.8 2.8 ± 3.6 <0.01
To pulmonary specialist 3.1 ± 2.9 2.9 ± 2.8 NS
Unscheduled physician visits 1.96 ± 2.9 1.72 ± 2.7 0.03
Emergency room visits 0.39 ± 0.8 0.31 ± 0.8 0.02
Hospitalizations 0.22 ± 0.7 0.22 ± 0.6 NS
NS: Non-significant.
the domain with the greatest deterioration during the 12 months
prior to ADMAPP (from 66.3 ± 21.7 to 70.3 ± 22.4). However,
by slope analysis, the activity domain deterioration significantly
stabilized by the end of year 2 (+4 vs. +0.56, respectively, p <
0.001). This slowing in deterioration of the activity domain
scores and stabilization of SGRQ total scores at the end of the
intervention year were observed across all age groups, including
the subgroup with the least HRQoL impairment at baseline (the
group >59 years) (Figure 2). Interestingly, this older group had
the least deterioration in all SGRQ scores during the intervention
year. This same pattern in SGRQ changes was observed across
all GOLD stages (not shown).
At study entry, participants had significant impairment in
the physical domain scores (PF, RP, GH, PCS) of the SF-36
compared with the general U.S. population (Table 2). Since
no consensus is available for interpreting SF-36 changes, in
order to evaluate the effect of ADMAPP on general HRQoL
we compared the proportion of individuals improving >1 SD
between the first and second year. There was a significant im-
provement in the proportion of subjects that report improve-
ments in VT, RE, PCS and particularly GH (Figure 3). There
were reciprocal changes of less worsening in these domains
(not shown).
Patient satisfaction
At the end of the intervention year, subjects were asked to
evaluate the effect the program had on them. Most stated that it
improved their knowledge about AATD and improved their cur-
rent treatment. Subjectively, the majority felt that their quality
of life either stabilized or improved (Figure 4).
DISCUSSION
This study showed that ADMAPP, a program designed to pro-
vide patient education using an original educational document
36 February 2009 COPD: Journal of Chronic Obstructive Pulmonary Disease
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Figure 2. Saint George Respiratory Questionnaire variation during the study period according to age groups. The slopes of SGRQ changes for
each of the study years are shown. The slopes were calculated by mixed model analysis using the baseline, 6th and 12th month measurement
for year 1 and 12th, 18th and 24th month measurements for year 2 (intervention year). *: p < 0.05.
enforced by regular telephone contacts, improves the patients’
knowledge of AATD and its treatment. This translates into more
optimal long-term and short-term medication use, and into pos-
itive changes in several patient-centered COPD outcomes such
as HRQoL, exacerbation rates and duration, unscheduled physi-
cian and ER visits, and overall patient satisfaction.
We studied a large group of individuals diagnosed with
AATD that were receiving augmentation therapy due to pul-
monary compromise. As a group, HRQoL at study entry was
severely impaired, with scores in SGRQ and SF-36 comparable
with those reported for older subjects included in other large
non-AATD COPD trials (17, 18). Although our study did not
have a control group without intervention, we believe that the
overall effect of ADMAPP on our subject’s HRQoL was a pos-
itive one. It has been shown that SGRQ total scores in COPD
deteriorate by a clinically significant degree (>4 points) every
15 months (18).
In contrast, our subjects had stable SGRQ scores throughout
the 24-month study. We observed that most of this reduction in
the rate of deterioration was due to a halt in decline in the activity
domain during the intervention year. We speculate that this effect
is directly related to improved medication use, in particular the
use of long acting bronchodilators, which have important effects
in stabilizing HRQoL (19, 20) and reducing exacerbations rates
(21, 22). This may also explain the observed improvement in
SF-36, particularly in the General Health domain, despite the
lack of increase in exercise habits. It is important to emphasize
that the benefits of the program were observed across all age
groups, with different levels of baseline HRQoL impairment.
The ADMAPP improved subject’s awareness about the sig-
nificance and consequences of acute exacerbations and the im-
portance of rapid optimal therapy. During the intervention year,
participants were more likely to use a course of short-term sys-
temic steroids to treat exacerbations and sought medical eval-
uation by a health professional more often. This appears to be
attributable to patients’ increased awareness of the worsening
of their symptoms and seeking of help, rather than to an adverse
effect of the disease management program. In contrast, the total
number of ER visits and unscheduled physician visits were sig-
nificantly less during the intervention year. Although this could
be due to a reduction in the total number and duration of exac-
erbations, an improved understanding of their disease may have
COPD: Journal of Chronic Obstructive Pulmonary Disease February 2009 37
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Figure 3. Proportion of subjects that improved SF-36 scores more than 10 points (1 standard deviation for the 1998 United States population)
during the pre-ADMAPP and ADMAPP (intervention) year. *: p < 0.05. BP: Bodily Pain; MH: Mental Health; VT: Vitality; RE: Role impairment
due to Emotional problems; SF: Social Function; RP: Role impairment due to Physical problems; GH: General Health; PF: Physical Functioning;
PCS: Physical Component Summary; MCS: Mental Component Summary.
provided patients with increased confidence in evaluating their
own symptoms, resulting in fewer visits or consultations with
their physicians.
Disease management programs have been previously eval-
uated in more traditional COPD cohorts but to the best of our
knowledge, this is the first trial to evaluate its effectiveness in
subjects with COPD associated with AATD. In COPD, dis-
ease management programs have beneficial effects on different
outcomes. For example, two studies evaluating disease-specific
education programs supported by weekly patient contact by
trained health professionals and an action plan, showed lower
hospital admissions for acute exacerbations, as well as decreased
ER and unscheduled physician visits (3, 23). In a systematic re-
view, interventions that included at least two chronic care model
components (also provided by the ADMAPP) led to lower rates
of ER and unscheduled visits as observed in our study (24).
Figure 4. Participant self-satisfaction survey after the ADMAPP (intervention) year.
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Improved medication use, such as increased use of sys-
temic steroid during exacerbations, resulted from a program
that combined self-education with short group sessions (25). Re-
garding HRQoL, some studies have shown improvements with
disease management programs (26) while others have shown no
differences between intervention and control groups (5, 6, 8).
In a recent review of randomized trials, it was concluded that
disease management plans overall have a positive effect in the
HRQoL of subjects with COPD (27). None of these programs
have been shown to affect mortality in patients with COPD. The
higher number of deaths observed during the second year of our
study suggests that despite the ADMAPP, subjects continued to
suffer from ongoing disease progression. Over the nine years
that AlphaNet has followed individuals with AATD, the annual
mortality rate has shown remarkable variability.
Most of the studied disease management programs in COPD
combine different strategies such as educational brochures (25,
26, 28), audiotapes (28), small group or individual education
sessions (3, 4, 6, 25, 28–30), home visits (3, 5), exercise pro-
grams (4) and action plans (3, 5–7, 25, 26, 30). Our program had
the particularity of being based on self-education reinforced by
frequent personalized phone calls by trained disease manage-
ment coordinators. These two features of the ADMAPP allow
reaching a large number of subjects with a wide geographic
distribution, as is the case with AATD-affected individuals.
This is particularly important for a population in which af-
fected individuals are scattered among the vast population of
patients with respiratory diseases with very few under the care
of physicians with specific expertise in AATD. It also allows
its application to patients undergoing care by different health
care professionals and health plans. In addition, the flexibility
of telephone call timing and the convenience of not leaving
home favors patient compliance. One limitation of our pro-
gram is that it lacks direct “face to face” interaction, and there-
fore may not allow effective exercise counseling and training
in breathing techniques or proper use of inhaled medications,
although these topics were covered with text and illustrations in
the BFRG.
The lack of a parallel control group to better estimate the
true effect of the program may be viewed as a limitation of our
study. Given the nature of our cohort, randomization of treat-
ment and controls would not have been possible. Since each of
the disease management coordinators supervised more than 100
subjects at a time, it was not practical to have them perform dif-
ferent types of calls to subjects who were part of the ADMAPP
or not. In addition, subjects with AATD in the United States
are frequently involved in support groups, receive newsletters,
and are in frequent contact with each other, which would have
jeopardized randomization. As an alternative, we used the same
cohort as its own control, observing baseline outcomes during
the year prior to the intervention. The wide geographical loca-
tion of the participants in our study did not allow us to gather
them for objective measures of exercise capacity and lung func-
tion. For the same reason, we chose to administer the surveys
via telephone calls, including the HRQoL instruments as de-
scribed in other studies (31, 32). The HRQoL data recorded,
with scores and impairment patterns similar to those reported in
other COPD studies (17, 18), suggests that our measurements
were reliable. Despite these efforts, the nature of the cohort and
the study design still does not eliminate the possibility of other
potential biases, which can only be controlled in randomized
clinical trials in this population.
The subjects with AATD studied in our cohort exhibited
marked impairment in several aspects of their life, despite being
a group with access to healthcare resources such as augmenta-
tion therapy. This highlights the importance of instituting efforts
such as the ADMAPP. To the best of our knowledge, this is the
first report that demonstrates that a self-management program,
that empowers AATD individuals to take a more active role in
the management of their disease, leads to beneficial effects in af-
fected individuals with severe lung disease. The positive effects
observed are particularly encouraging given that our subjects
were already self-motivated, as evidenced by their high rate of
participation and low dropout rates. It is possible that a longer
follow-up may have allowed us to document further improve-
ments in outcomes, given that not all subjects comprehend the
educational material at the same pace and many need a longer
time to incorporate the lifestyle changes recommended by the
program. The longer-term effects of the ADMAPP warrant on-
going evaluation.
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